Previous 10 | Next 10 |
Clinical responses and durable activity with agenT-797 monotherapy and in combination with anti-PD-1 First-of-a-kind persistence for an allogeneic cell therapy, with agenT-797 detected for up to 6 months without toxic pre-conditioning AgenT-797 advancing in a randomized phase 2 tr...
NEW YORK, Oct. 30, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other...
NEW YORK, Sept. 27, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other imm...
NEW YORK, Aug. 24, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune...
2023-08-23 05:36:55 ET Summary MiNK Therapeutics is developing "off the shelf" allogeneic cell therapies for cancer using iNKT cells. Their first iNKT cell therapy, agenT-797, showed a pro-inflammatory cytokine response and some efficacy in patients with solid tumors. The comp...
- Randomized Phase 2 Trial in 2L Metastatic Gastric Cancer Planned to Launch at Memorial Sloan Kettering Cancer Center - iNKT (agenT-797) Data Presented at AACR, ASGCT, and ATS Showed Benefit in Solid Tumor Cancers and in Respiratory Distress - MiNK-2...
Company announces participation in BTIG Virtual Biotechnology Conference NEW YORK, July 28, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-stage biopharmaceutical company specializing in the discovery, development and commercialization of allogeneic, off-the-shelf, ...
75% survival in patients with severe respiratory distress treated with agenT-797 agenT-797 improved lung function, significantly reduced inflammation and secondary infections MiNK to advance agenT-797 in ARDS through externally financed programs NEW YORK, May 22, 2023 (GLOBE NEWSW...
FAP-CAR-IL-15 iNKT cell therapy (MiNK-215) promotes curative responses driving tumor elimination and immune infiltration in NSCLC models IND enabling studies underway; IND filing on track for 2024 NEW YORK, May 18, 2023 (GLOBE NEWSWIRE) -- MiNK Therapeutics (Nasdaq: INKT), a clinical-st...
2023-05-14 14:25:03 ET MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Conference Call May 11, 2023 8:30 AM ET Company Participants Zack Armen – Head-Investor Relations Jennifer Buell – President and Chief Executive Officer Marc Van Dijk – Ch...
News, Short Squeeze, Breakout and More Instantly...
MiNK Therapeutics Inc. Company Name:
INKT Stock Symbol:
NASDAQ Market:
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the Ameri...
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS) AACR presentation reported MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models...